Miyata, Shoko
Saku, Noriaki
Akiyama, Saeko
Javaregowda, Palaksha Kanive
Ite, Kenta
Takashima, Nagisa
Toyoda, Masashi
Yura, Kei
Kimura, Tohru
Nishina, Hiroshi
Nakazawa, Atsuko
Kasahara, Mureo
Nonaka, Hidenori
Kiyono, Tohru
Umezawa, Akihiro
Article History
Received: 18 April 2021
Accepted: 5 December 2021
First Online: 10 January 2022
Declarations
:
: Human cells in this study were performed in full compliance with the Ethical Guidelines for Clinical Studies (Ministry of Health, Labor, and Welfare, Japan). The cells were banked after approval of the Institutional Review Board at the National Institute of Biomedical Innovation (May 9, 2006). Animal experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee of the National Research Institute for Child Health and Development.
: Not applicable.
: AU is a co-researcher with MTI Ltd., Terumo Corp., BONAC Corp., Kaneka Corp., CellSeed Inc., ROHTO Pharmaceutical Co., Ltd., SEKISUI MEDICAL Co., Ltd., Metcela Inc., PhoenixBio Co., Ltd., Dai Nippon Printing Co., Ltd. AU is a stockholder of TMU Science Ltd., Morikuni Ltd., and Japan Tissue Engineering Co., Ltd. The other authors declare that there is no conflict of interest regarding the work described herein. All authors have read and approved the manuscript. AU is the associate editor of the journal and was not involved in the peer review process of the article.